$RPTX News
Last published 10mo ago
- 10mo agoRPTXRepare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total ConsiderationBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's
- 11mo agoRPTXRepare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.Business WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive
- 12mo agoGLMDKBLBRPTXZYMEKey Catalysts Emerge in Oncology, Synthetic Biology, and M&A Activity as Markets OpenGlobeNewswireDENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Markets open this morning with a distinctly biotech-heavy narrative delivering milestone developments. Zymeworks and Jazz Drop Landmark Phase 3 Data: Ziihera Positioned as New
- 12mo agoRPTXRepare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.Business Wire- Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 2026 - - Additional portfolio monetization efforts continue - -
- 1y agoRPTXRepare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase
- 1y agoRPTXRepare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsBusiness WireEntered into worldwide licensing agreement with Debiopharm for lunresertib Evaluating strategic alternatives to maximize shareholder value Initial data for LIONS and POLAR trials expected to be reported in Q4
- 1y agoIMNMINSMKURARPTXOMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit CommitteeGlobeNewswirePRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a
- 1y agoRPTXRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm
- 1y agoRPTXNewly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug ConjugatesBusiness WireCombines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined
- 1y agoRPTXRepare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx BiotherapeuticsBusiness WireRepare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program
- 1y agoRPTXRepare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025Business WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of
- 1y agoRPTXRepare Therapeutics Announces Leadership TransitionsBusiness WireSteve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and Director to pursue
- 1y agoRPTXRepare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced that the Compensation Committee of the Company's Board of Directors granted, on November
- 1y agoRPTXRepare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireInitial clinical readout from Phase 1 RP-3467 (Polθ ATPase/helicase inhibitor) POLAR trial expected in Q3 2025 Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025 Company
- 1y agoRPTXRepare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost ReductionsBusiness WireRealigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring
- 1y agoONCYCRGXIMRXRNXT+1How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment OptionsPR NewswireUSA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...
- 1y agoONCYCRGXIMRXRNXT+1How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment OptionsPR NewswireUSA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies...
- 1y agoRPTXRepare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical TrialBusiness WireHeavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer Nearly half of patients with
- 1y agoRPTXRepare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical TrialBusiness WireEvent to be webcast live on Thursday, December 12 at 4:30 p.m. ET Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced it will host a
- 2y agoRPTXRepare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of CamonsertibBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed to
- 2y agoRPTXRepare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial ResultsBusiness WireOn track to report data from the ongoing MYTHIC dose expansion clinical trial at the recommended Phase 2 dose (RP2D) at a company event in December 2024, with the plan to begin a registrational trial in 2025 Presented
- 2y agoRPTXRepare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical TrialBusiness WireData presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today
- 2y agoRPTXRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase InhibitorBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's Phase 1 (POLAR) clinical trial
- 2y agoRPTXRepare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual MeetingBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported data highlighting the clinical benefits of camonsertib, a potential best-in-class
- 2y agoRPTXRepare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic CancersBusiness WireData presented at AACR's Ovarian Cancer Research Symposium confirm that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7 or PP2R1A mutations carry poor prognosis Significant survival disparities were
- 2y agoRPTXRepare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024Business WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the Company will share new data from Module 1 of its ongoing Phase 1/2 TRESR
- 2y agoRPTXRepare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioBusiness WireFocuses Company's resources on its deep clinical oncology pipeline Positioned to advance four clinical programs through multiple upcoming milestones Repare Therapeutics Inc. ("Repare" or the "Company")
- 2y agoRPTXRepare Therapeutics to Participate in Two Upcoming Investor ConferencesBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor
- 2y agoRPTXRepare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial ResultsBusiness WireReiterated guidance on data readout from MYTHIC trial evaluating lunresertib and camonsertib in patients with platinum-resistant ovarian and endometrial cancers in Q4 2024 Granted Fast Track designation by the FDA for
- 2y agoRPTXRepare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRIBusiness WireOverall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of
- 2y agoRPTXRepare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company's camonsertib monotherapy
- 2y agoRPTXRepare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian CancerBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to
- 2y agoRPTXRepare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at
- 2y agoRPTXRepare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024Business WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in
- 2y agoRPTXRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsBusiness WirePhase 1 MYTHIC clinical trial of lunresertib in combination with camonsertib demonstrated a significant reduction in Grade 3 anemia and continued trends of patient response and benefit; FDA agrees with
- 2y agoRPTXRepare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 InhibitionBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, and Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company
- 2y agoRPTXDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 InhibitionBusiness WireDebiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, and Repare Therapeutics Inc. ("Repare")
- 2y agoRPTXRepare Therapeutics Appoints Steven H. Stein, M.D. to its Board of DirectorsBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as
- 2y agoRPTXRepare Therapeutics to Participate in Two Upcoming Investor ConferencesBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two upcoming
- 2y agoRPTXRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31,
- 2y agoRPTXKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)Business WireThe law firm of Kirby McInerney LLP is invest
- 2y agoRPTXRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664Business WireRP-1664 is a Potential First-in-Class, Selective, PLK4 Inhibitor Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the first
- 2y agoRPTXRepare Therapeutics to Regain Global Rights to CamonsertibBusiness WireRepare will regain control of its potential best-in-class oral small molecule ATR inhibitor Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company,
- 2y agoRPTXRepare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone PaymentBusiness WireMilestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche's Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in potential milestones, plus
- 2y agoRPTXRepare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 MilestonesBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. "We
- 2y agoRPTXDebiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in CancerBusiness WireCollaborative clinical study will investigate a novel combination of Debio 0123, Debiopharm's potent, brain penetrant inhibitor of WEE1, and lunresertib, Repare Therapeutics' first-in-class PKMYT1 inhibitor Debiopharm
- 2y agoRPTXRepare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in CancerBusiness WireCollaborative clinical study will investigate a novel combination of lunresertib, Repare's first-in-class PKMYT1 inhibitor, and Debio 0123, Debiopharm's potent, brain-penetrant inhibitor of WEE1 Repare Therapeutics
- 2y agoRPTXRepare Therapeutics Insiders Establish Automatic Securities Disposition PlansBusiness WireRepare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel
- 2y agoRPTXRepare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ InhibitorBusiness WireRP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination
- 3y agoRPTXRepare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial ResultsBusiness WirePresented positive initial data from ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, including an overall RECIST response rate of 50% in patients with heavily